Current and future development of extended-release, abuse-deterrent opioid formulations in the United States

References

• Rudd RA, Aleshire N, Zibbell JE, et al. Increases in drug and opioid overdose deaths - United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64:1378–1382.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2015 national survey on drug use and health. Rockville (MD): US Department of Health and Human Services; 2016. ( HHS Publication No. (SMA) 16-4984).
   Google Scholar
• Centers for Disease Control and Prevention. Wide-ranging online data for epidemiologic research (WONDER), multiple cause of death data. [cited 2016 Apr 25]. Available from: http://www.cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf
   Google Scholar
• National Institute on Drug Abuse. Prescription opioids and heroin. Rockville (MD): US Department of Health and Human Services; 2015.
   Google Scholar
• US Department of Health and Human Services. Addressing prescription drug abuse in the United States current activities and future opportunities. Washington, DC: US Department of Health and Human Services; 2013.
   Google Scholar
• Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64:453–458.
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657–667.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–63.
   PubMed Web of Science ®Google Scholar
• Bartoli A, Michna E, He E, et al. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain. Postgrad Med. 2015;127:5–12.
   PubMed Web of Science ®Google Scholar
• Katz N, Kopecky EA, O’Connor M, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain. 2015;156:2458–2467.
   PubMed Web of Science ®Google Scholar
• Rauck RL, Hale ME, Bass A, et al. A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment. Pain. 2015;156:1660–1669.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO’s cancer pain ladder for adults. [cited 2015 Dec 1]. Available from: http://www.who.int/cancer/palliative/painladder/en/
   Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65:1–49.
   PubMed Web of Science ®Google Scholar
• Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. N Engl J Med. 2016;374:1480–1485.
   PubMed Web of Science ®Google Scholar
• Brown J, Setnik B, Lee K, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011;7:467–483.
   PubMedGoogle Scholar
• Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15:ES67–92.
   PubMed Web of Science ®Google Scholar
• Scholten W, Henningfield JE. Negative outcomes of unbalanced opioid policy supported by clinicians, politicians, and the media. J Pain Palliat Care Pharmacother. 2016;30:4–12.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry: abuse-deterrent opioids – evaluation and labeling. Silver Spring (MD): US Department of Health and Human Services; 2015.
   Google Scholar
• State Pain Policy Finder: Legislation & Regulation. [cited 2016 Oct 31]. Available from: http://sppan.aapainmanage.org/legislation
   Google Scholar
• Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–2296.
   PubMed Web of Science ®Google Scholar
• Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205–217.
   PubMed Web of Science ®Google Scholar
• Omidian A, Mastropietro DJ, Omidian H. Reported methods of abuse of common prescription analgesic opioids. J Develop Drugs. 2014;3. DOI:10.4172/2329-6631.1000120
   Google Scholar
• Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;168:219–229.
   PubMed Web of Science ®Google Scholar
• Volkow ND. What science tells us about opioid abuse and addiction. [cited 2016 Apr 28]. Available from: https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2016/what-science-tells-us-about-opioid-abuse-addiction
   Google Scholar
• Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142–1154.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84:602–612.
   PubMed Web of Science ®Google Scholar
• Lipman AG. What have we learned from OxyContin? J Pain Palliat Care Pharmacother. 2003;17:1–4.
   Google Scholar
• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657–1675.
   PubMed Web of Science ®Google Scholar
• Hale ME, Moe D, Bond M, et al. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016;6:497–508.
   PubMed Web of Science ®Google Scholar
• Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18:255–263.
   PubMed Web of Science ®Google Scholar
• Unprecedented diversion-/abuse-resistance: molecular deactivation of opioid drugs. [cited 2016 Sep 27]. Available from: https://www.sbir.gov/sbirsearch/detail/706397
   Google Scholar
• Cone EJ, Sokolowska M, Lindhardt K. Striving for consensus on approaches to category 1 testing of abuse-deterrent formulations of opioids: discussions from the first category 1 focus group meeting. Pain Pract. 2016;16:809–813.
   PubMed Web of Science ®Google Scholar
• Sellers EM, Shram MJ, Schoedel KA. The US FDA draft guidance for developing abuse-deterrent opioid analgesics: 2014 and beyond. Pharm Med. 2014;28:317–327.
   Google Scholar
• Bartholomaus J, Schwier S, Brett M, et al. New abuse deterrent formulation (ADF) technology for immediate-release opioids. Drug Dev Deliv. 2013;13:76–81.
   Google Scholar
• Kopecky EA, Fleming AB, Noonan PK, et al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx(R): an extended-release, abuse-deterrent formulation. J Opioid Manag. 2014;10:233–246.
   PubMedGoogle Scholar
• Perrino PJ, Colucci SV, Apseloff G, et al. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin® tablets compared with original OxyContin® tablets in healthy adults. Clin Drug Investig. 2013;33:441–449.
   PubMed Web of Science ®Google Scholar
• Comer SD, Ashworth JB, Sullivan MA, et al. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5:203–212.
   PubMedGoogle Scholar
• Webster LR, Kopecky EA, Smith MD, et al. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med. 2016;17:1112–1130.
   PubMed Web of Science ®Google Scholar
• Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62:1481–1502.
   PubMed Web of Science ®Google Scholar
• Walden M, Nicholls FA, Smith KJ, et al. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm. 2007;33:1101–1111.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA asks Purdue Pharma to withdraw palladone for safety reasons. [cited 2015 Dec 4]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108460.htm
   Google Scholar
• Embeda (Morphine Sulfate and Naltrexone Hydrochloride Capsule Extended Release). Full prescribing information [package insert]. New York (NY): Pfizer Inc; 2014.
   Google Scholar
• Morasco BJ, Turk DC, Donovan DM, et al. Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 2013;127:193–199.
   PubMed Web of Science ®Google Scholar
• Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289:2370–2378.
   PubMed Web of Science ®Google Scholar
• Sheu R, Lussier D, Rosenblum A, et al. Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Med. 2008;9:911–917.
   PubMed Web of Science ®Google Scholar
• Harris SC, Cipriano A, Kapil RP, et al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2016;pnw208. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Webster LR, Pantaleon C, Shah MS, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine-morphine ARER. Pain Med. 2016;pnw213. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Chen L, Bonson KR. An equivalence test for the comparison between a test drug and placebo in human abuse potential studies. J Biopharm Stat. 2013;23:294–306.
   PubMed Web of Science ®Google Scholar
• Oxycontin (Oxycodone Hydrochloride Tablet Film Coated Extended Release). Full prescribing information [package insert]. Stamford (CT): Purdue Pharma LP; 2015.
   Google Scholar
• Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (Oxycontin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016;100:275–286.
   PubMed Web of Science ®Google Scholar
• Eaton TA, Comer SD, Revicki DA, et al. Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations. Qual Life Res. 2012;21:975–981.
   PubMed Web of Science ®Google Scholar
• White AG, LeCates J, Birnbaum HG, et al. Positive subjective measures in abuse liability studies and real-world nonmedical use: potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. J Opioid Manag. 2015;11:199–210.
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2013 national survey on drug use and health: summary of national findings. Rockville (MD): US Department of Health and Human Services; 2014. ( HHS Publication No. (SMA) 14-4863).
   Google Scholar
• Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013;130:13–23.
   PubMed Web of Science ®Google Scholar
• Schatman ME, Webster LR. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. J Pain Res. 2015;8:153–158.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry: general principles for evaluating the abuse deterrence of generic solid oral opioid drug products. Silver Spring (MD): US Department of Health and Human Services; 2016.
   Google Scholar